Preclinical
Three venture capitalists debuted Dimension I Wednesday, a new fund with $350 million to fuel modern biotech.
Results from a study published in PNAS demonstrated that delivering therapeutics intranasally was sufficient to enhance functional recovery in rat models of ischemic stroke.
Thursday, Astellas announced that the FDA had lifted its clinical hold for the company’s experimental gene therapy trial for late-onset Pompe disease.
TC BioPharm and MD Anderson signed a three-year collaboration to better understand the role of gamma delta T cells in cancer treatment.
A novel base editing approach shows a cardioprotective effect in a preclinical study.
Cambrian Biopharma announced that its latest pipeline company, Isterian Biotech, has emerged from stealth to develop first-in-class medicines to tackle aging.
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.
In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.
Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.
PRESS RELEASES